Boston Scientific (BSX) Azione Prezzo
Boston Scientific Prezzo
Il fatturato è cresciuto a un tasso composto del 5,1% annuo negli ultimi 19 anni, raggiungendo 20,07 miliardi USD. L'utile per azione è cresciuto del 14,1% all'anno negli ultimi 14 anni. Il margine netto di Boston Scientific si attesta al 14,4%, in aumento rispetto al 8,7% di alcuni anni fa. Gli analisti fissano un target di prezzo mediano di 63,50 USD, ovvero il 49,7% sopra il prezzo attuale. Su 37 analisti, 29 valutano il titolo come acquisto — nel complesso un consenso Acquistare.
Boston Scientific Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Boston Scientific Azione e analisi azionaria
Domande frequenti sull'azione Boston Scientific
The main competitors of Boston Scientific Corp in the market include Medtronic, Johnson & Johnson, Abbott Laboratories, and Edwards Lifesciences.
Boston Scientific Corp is a global medical technology company. Its business model revolves around developing innovative medical solutions that enhance patient care and healthcare outcomes. Boston Scientific Corp manufactures and markets a broad range of medical devices used in various specialties, such as cardiology, urology, endoscopy, and neuromodulation. The company's commitment to research and development enables it to introduce advanced technologies and therapies that address unmet clinical needs. Boston Scientific Corp also focuses on collaborations and partnerships to expand its product portfolio, improve access to healthcare, and provide high-quality medical devices to patients worldwide.
Boston Scientific Corp is primarily active in the medical equipment and supplies industry.
Boston Scientific Corp is a renowned medical technology company based in Marlborough, Massachusetts. Established in 1979, it has become a global leader in the development, manufacturing, and marketing of innovative medical devices. With a focus on advancing patient care, Boston Scientific Corp offers a wide range of products for various medical specialties, including interventional cardiology, urology, endoscopy, and neuromodulation. The company's history showcases its commitment to medical breakthroughs and improving the lives of patients worldwide. Boston Scientific Corp's dedication to cutting-edge technology and strategic acquisitions has allowed it to maintain a prominent position in the healthcare industry.
Boston Scientific Corp has achieved significant milestones throughout its history. Some notable achievements include the development of the Taxus Express, a groundbreaking drug-eluting stent that revolutionized the treatment of coronary artery disease. Additionally, the acquisition of Guidant Corporation strengthened Boston Scientific's position in the field of cardiac rhythm management. The company's innovative products, such as the Watchman Left Atrial Appendage Closure device, have provided improved treatment options for patients with atrial fibrillation. Boston Scientific Corp continues to innovate and make advancements in medical technologies, helping to improve patient outcomes worldwide.
Boston Scientific Corp is primarily present in several countries and regions worldwide. The company has a strong global presence, with significant operations in the United States, Europe, Asia-Pacific, Latin America, and the Middle East. Its diverse market reach spans across more than 130 countries, enabling Boston Scientific Corp to provide innovative medical solutions and technologies to a vast range of patients and healthcare professionals worldwide.
Boston Scientific Corp represents values of innovation, collaboration, and patient-centricity. With a strong corporate philosophy focused on improving patients' lives, the company is committed to developing and delivering innovative medical solutions. Boston Scientific Corp's dedication to collaboration extends to its partnerships with healthcare professionals and institutions, helping to address unmet needs and improve patient outcomes. By prioritizing patient-centric care, the company ensures that its products and services are designed to provide effective and meaningful treatments. Boston Scientific Corp's continued commitment to innovation and collaboration underscores its mission to transform lives through medical advancements in a rapidly evolving healthcare landscape.
Gli analisti fissano attualmente un prezzo obiettivo medio di 66,50 USD per l’azione Boston Scientific (mediana: 63,50 USD), pari a +56,7 % rispetto all’ultimo prezzo. Il consenso si basa su 37 giudizi di analisti.
37 analisti valutano attualmente l’azione Boston Scientific: 29 raccomandano l’acquisto, 8 la tenuta e 0 la vendita. Per il 2026 gli analisti si aspettano per Boston Scientific ricavi pari a 21,19 miliardi USD e un utile per azione di 3,22 USD.
Convertita al tasso di cambio attuale, l’azione Boston Scientific quota 38,01 EUR (42,43 USD).
L’azione Boston Scientific (BSX) è quotata su 10 borse, tra cui: NYSE (BSX), London (0HOY.L), SIX (Zürich) (BSX.SW), XETRA (BSX.DE), Frankfurt (BSX.F), München (BSX.MU), Düsseldorf (BSX.DU), Wien (BSXC.VI).
The Boston Scientific Corporation is a medical technology company that specializes in the manufacturing and development of medical devices. The company was founded in Massachusetts in 1979 and operates globally today. Its business model includes various divisions that focus on different medical specialties. The Cardiac Rhythm Management division of Boston Scientific is involved in the manufacturing of devices for the treatment of heart rhythm disorders. This includes products such as implantable defibrillators, pacemakers, and accessories. The products in this division are of high quality and have an excellent track record in treating patients with severe heart problems. The Interventional Cardiology division of Boston Scientific specializes in the manufacturing of products used in the treatment of heart diseases. This includes balloon catheters, stents, and catheter ablation systems. These products are typically minimally invasive and allow for a quick restoration of normal heart rhythm in patients. The Interventional Radiology division of Boston Scientific is focused on the manufacturing of products for the diagnosis and treatment of vascular diseases. The company produces catheters, stents, and embolization accessories, among other things. Additionally, Boston Scientific is also specialized in the development of products for the treatment of chronic pain. The products in this division include implantable pain therapy systems, neurostimulators, and accessories. These devices can alleviate patients' pain and improve their quality of life. The company is also specialized in the field of urology, including products for the treatment of conditions such as urinary incontinence and benign prostatic hyperplasia. Boston Scientific produces mesh implants and devices aimed at improving bladder control. Furthermore, the company has a division dedicated to gastrointestinal diseases, including products for the treatment of conditions like colorectal cancer and gastrointestinal bleeding. The portfolio includes endoscopes, balloon catheters, and other devices for the treatment of digestive tract disorders. Boston Scientific is committed to providing its customers with the best products. Product development is strongly focused on meeting the needs of patients and doctors. By continually developing new products, the company can expand its market position and maintain its leading position in the medical technology industry.
Il attesa fatturato di Boston Scientific ammonta a 21,19 miliardi USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Boston Scientific ammonta a 4,81 miliardi USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Boston Scientific è attualmente 13,18. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Boston Scientific.
Il rapporto prezzo/fatturato (P/S) di Boston Scientific è attualmente 3,00. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Boston Scientific.
Il Quality Score AlleAktien per Boston Scientific è 5/10.
L'ISIN di Boston Scientific è US1011371077. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Boston Scientific è 884113. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Boston Scientific è BSX. Con questo simbolo di borsa vengono negoziate le azioni Boston Scientific in borsa.
Azione Boston Scientific
Gruppo di pari di Boston Scientific
Boston Scientific Ticker
Boston Scientific FIGI
Altre metriche e analisi di Boston Scientific in Deep Dive.
La nostra analisi azionaria dell'azione Boston Scientific include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Boston Scientific. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: